麗珠醫藥(01513.HK)在印度尼西亞設立合資公司
格隆匯7月29日丨麗珠醫藥(01513.HK)公吿,2024年7月29日,公司全資附屬公司LIAN SGP HOLDING PTE.LTD.與PT KALBE FARMA,TBK.控股附屬公司PT GLOBAL CHEMINDO MEGATRADING簽署了《SHAREHOLDERS’AGREEMENT》,公司和Kalbe通過附屬公司以現金方式出資在印度尼西亞設立合資公司。合資公司的授權資本為1,306,080,000,000印尼盾,即1,306,080股。
合資公司成立後,將發行25%普通股,即326,520股,其中,LIANSGP出資261,216,000,000印尼盾認購合資公司261,216股普通股,佔合資公司初始發行股份的80%,PTGCM出資65,304,000,000印尼盾認購合資公司65,304股普通股,佔合資公司初始發行股份的20%。合資公司主要從事原料藥生產業務。
本次公司對外投資在印度尼西亞設立合資公司,有利於公司拓展海外業務,符合公司中長期戰略發展的目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.